Sirtris Pharmaceuticals to Present at the Sixth Annual Needham & Company Biotechnology and Medical Technology Conference June 13
June 12 2007 - 10:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that it will be presenting at the Sixth Annual Needham &
Company Biotechnology and Medical Technology Conference on June 13,
2007 at 9:30 a.m. EDT in New York. The presentation will be webcast
live and can be accessed on the Sirtris website,
www.sirtrispharma.com, in the investor relations section. A replay
will be available approximately twenty-four hours after the
presentation and will be available on the company�s website for two
weeks. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a
biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 concerning Sirtris
Pharmaceuticals, its product candidates, and those candidates'
clinical potential. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the Company's
potential inability to initiate and complete preclinical studies
and clinical trials for its product candidates, the fact that none
of the Company's product candidates has received regulatory
approvals, the potential inability of the�Company to gain market
acceptance of the Company's product candidates, and those other
risks factors�that can be found in the�Company's filings with the
Securities and Exchange Commission. Actual results may differ
materially from those Sirtris Pharmaceuticals contemplated by these
forward-looking statements. Sirtris Pharmaceuticals does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Aug 2023 to Aug 2024